突发！辉凌启动全球裁员500人

Core Insights - Ferring Pharmaceuticals announced a global workforce reduction plan, laying off 500 employees, approximately 7% of its total workforce, as part of a broader restructuring and operational optimization initiative [1][2] Group 1: Restructuring and Workforce Changes - The layoffs are part of a comprehensive restructuring plan aimed at enhancing strategic focus, improving cost efficiency, and increasing organizational flexibility [1][2] - The company has previously implemented workforce reductions, including 134 layoffs in 2024 and the closure of a research facility in San Diego in 2023, indicating a trend towards consolidating resources in high-priority areas [3] - The restructuring includes the establishment of a new "Science, Medicine, and Development Committee" to provide centralized professional support for R&D decisions [2] Group 2: Strategic Focus and Future Direction - Ferring plans to increase investments in "modern technologies" and shift its business development focus towards "mid-to-late stage opportunities," suggesting a move away from early-stage R&D [2] - The company is also expanding its production capacity, having built a new facility in Kuopio, Finland, to produce active pharmaceutical ingredients for its key product, Adstiladrin, which was approved by the FDA in late 2022 [4] - Ferring reported a sales revenue of €2.3 billion (approximately $2.7 billion) for the fiscal year 2024, with its reproductive medicine business line surpassing €1 billion in annual sales, providing a solid financial foundation for the restructuring [4]